Products
Erzotabart Biosimilar Monoclonal Antibody (CD38) for Research
Cat No.: GMP-Bios-INN-1189
Anti-ADPRC1/CD38 therapeutic antibody (Pre-made Erzotabart biosimilar,Whole mAb) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).
Erzotabart (development code GEN-3014) is a monoclonal antibody targeting CD38. It is developed by Genmab for haematological malignancies. It is in Phase I/II clinical development.
Order Information
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. →
| Catalog No. | Package | Price(In USD) |
|---|---|---|
| GMP-Bios-INN-1189-1mg | 1mg | 3090 |
| GMP-Bios-INN-1189-10mg | 10mg | |
| GMP-Bios-INN-1189-100mg | 100mg | |
| GMP-Bios-INN-1189-xmg | ≥100mg |
Product Details
| Products Name (INN Index) | Pre-Made Erzotabart biosimilar, Whole mAb, Anti-ADPRC1/CD38 Antibody: Anti-CD38/ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1/2'-phospho-ADP-ribosyl cyclase therapeutic antibody |
| INN Name | Erzotabart |
| Target | ADPRC1/CD38 |
| Format | Whole mAb |
| Derivation | Human |
| Species Reactivity | Human |
| CH1+2+3 Isotype | G1 |
| VD LC | Kappa |
| Highest_Clin_Trial (Jan '20) | Phase-I/II |
| Est. Status | Active |
| 100% SI Structure | 8byu:HL |
| 99% SI Structure | None |
| 95-98% SI Structure | None |
| Year Proposed | 2023 |
| Year Recommended | 2023 |
| Companies | Genmab |
| Conditions Approved | na |
| Conditions Active | Haematological malignancies |
| Conditions Discontinued | na |
| Production | na |
| Development Tech | na |
